The Dermatology Digest

SEPTEMBER 9, 2024

“China has always been a strategic market for Sisram, and the approval of Daxxify serves as a key milestone for bringing Sisram’s high-end injectables portfolio to Mainland China,” says Mr. Liu Yi, Sisram Chairman and Executive Director, in a news release. and Abroad appeared first on The Dermatology Digest.

Portfolios 36

Portfolios Dermatology Injections Marketing 36

The Dermatology Digest

JANUARY 16, 2024

Mr. Foard joined Sanofi in March 2017 as the Global Head of Dermatology and Respiratory, and held roles of increasing responsibility, including as Head of Global Immunology for Sanofi. Ferris, MD, PhD, Professor of Dermatology, University of Pittsburgh School of Medicine, and a participant in the study, in a news release.

Dermatology 36

Dermatology Microneedling Technology Cosmetic Products 36

The Dermatology Digest

JULY 31, 2024

to exclusively promote, market, sell and distribute select SkinCeuticals products to medical and physician-led clinics in Japan. “We Under the terms of the agreement, the partnership will initially span three years, with options for renewal. Relfydess also received a marketing authorization in Australia earlier this year.

Dermatology 36

Dermatology Technology Sustainability Marketing 36

The Dermatology Digest

DECEMBER 20, 2023

Mr. Raducha-Grace recently served as Head of Clinical Partnerships at Harbor Health. Before Harbor Health, he led product and go-to-market functions for CVS’s kidney care and home business units. Head of the SAB, Is a Professor of Dermatology with Penn State Health Hershey Medical Center, and Penn State College of Medicine.

Dermatology 36

Dermatology Surgery Eczema Office 36

The Dermatology Digest

SEPTEMBER 30, 2024

market, is an important milestone on our pathway to consistently broadening our biopharma portfolio in the U.S. In February 2023, Fresenius Kabi and Formycon entered into a global commercialization partnership for the ustekinumab biosimilar candidate covering key global markets. and worldwide.

Portfolios 36

Portfolios Partnerships Marketing Safety 36

The Dermatology Digest

FEBRUARY 27, 2024

While both low-concentration and high-concentration strength biosimilars of Humira are marketed in the U.S. This approval marks an important milestone for Teva and Alvotech’s partnership to collaborate on seven biosimilars and expand the availability, access, and uptake of biosimilars in the U.S.” today, nearly 88% of U.S.

Safety 36

Safety Marketing Pharmaceutical Partnerships 36

The Dermatology Digest

MARCH 20, 2024

. “We are delighted to partner with the Miami Open as the official sunscreen sponsor,” says Guillaume Monsel, Vice President of Marketing at La Roche-Posay, in a news release. “At La Roche-Posay, we are passionate about bringing dermatological skincare to all with our mission to improve the quality of life of our patients.

Branding 36

Branding Partnerships Safety Dermatology 36

The Dermatology Digest

FEBRUARY 12, 2024

The entire three-week campaign was executed across digital media, video, social media and CeraVe brand channels, in addition to a robust influencer marketing strategy. It needed to be an unforgettable skincare education journey,” says Tom Allison, SVP & Global Head of Professional Sales and Marketing.

Social Media 36

Social Media Branding Marketing Partnerships 36

The Dermatology Digest

JANUARY 4, 2024

Joint development for DMB-3115 was initiated in 2013 by Dong-A Socio Holdings and Meiji Seika Pharma, with exclusive commercialization rights granted to Intas Pharmaceuticals through a partnership announced in 2021. market during the next five years. commercialization. president of Accord, in a news release.

Pharmaceutical 36

Pharmaceutical Partnerships Clinic Safety 36

The Dermatology Digest

DECEMBER 21, 2023

“We are increasingly optimistic about the near-term potential that the next-generation technology in the Evolysse and Estyme fillers lines will offer customers in the fast-growing facial HA market. We are extremely excited to expand our partnership with Evolus beyond the U.S. to now include the U.K. to now include the U.K.

Marketing 36

Marketing Sales Branding Portfolios 36

The Dermatology Digest

DECEMBER 21, 2023

“We are increasingly optimistic about the near-term potential that the next-generation technology in the Evolysse and Estyme fillers lines will offer customers in the fast-growing facial HA market. We are extremely excited to expand our partnership with Evolus beyond the U.S. to now include the U.K. to now include the U.K.

Marketing 36

Marketing Sales Branding Portfolios 36

The Dermatology Digest

JUNE 24, 2024

The two-day course offered an in-depth education on AviClear clinical techniques, consultative strategies, including practice insights and marketing strategies. At Cutera, we believe in the power of partnerships,” adds Taylor Harris, CEO of Cutera.

Partnerships 36

Partnerships Marketing Education Tools 36

The Dermatology Digest

MARCH 7, 2024

Cutera is expanding its advanced education and marketing programs for practices in North America to support customer success with AviClear and other Cutera products. “These investments in training and marketing align to our mission as we become a partnership-driven company.” . AviClear is U.S.

Marketing 36

Marketing Partnerships Education Tools 36

The Dermatology Digest

APRIL 4, 2025

Tildrakizumabhas also been approved for moderate-to-severe plaque psoriasis inAustralia andJapan, and under the brand name IlumetriinEurope, where it is marketed by Almirall. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, inthe United States.

Partnerships 41

Partnerships Treatments Marketing Branding 41

The Dermatology Digest

NOVEMBER 13, 2024

The partnership with Maddie & Tae is a powerful testament to Dial’s brand commitment to empowering everyone to confidently engage in everyday moments of connection. says Allison Feldman, VP Marketing – Personal Care Brands at Henkel, in a news release.

Social Media 36

Social Media Branding Partnerships Extractions 36

The Dermatology Digest

MARCH 27, 2025

have entered into a collaboration and licensing agreement to develop, manufacture, and commercialize ESK-001, a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor, for dermatology indications in Japan, with the option to expand the license to include rheumatological and gastrointestinal diseases. Alumis Inc.

Pharmaceutical 36

Pharmaceutical Portfolios Clinic Safety 36

The Dermatology Digest

APRIL 17, 2025

Many partnership agreements have already been signed and others are under negotiation. appeared first on The Dermatology Digest. We are pleased to enter into this agreement with Mayne Pharma, says Mori Arkin, Chairman of the Board and CEO of Sol-Gel, in a news release. Having concluded this U.S. business alone.

Rosacea 36

Rosacea Clinic Partnerships Sales 36